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Abstract  
Background: Cardiovascular diseases (CVD) represent a major health issue in patients with schizophrenia 
(SCZ) and bipolar disorder (BD), but the exact nature of cardiometabolic (CM) abnormalities involved and 
the underlying mechanisms remain unclear. Psychiatric medications are known risk factors, but it is unclear 
whether there is a connection between the psychiatric disorders (SCZ/BD) themselves and CM abnormalities.   
 
Objective: To examine polygenic associations between SCZ/BD with CM traits, explore possible causal 
relationships between them, and identify shared genetic loci and pathways.  
 
Design: Using polygenic risk scores (PRS) and LD score regression, we investigated the shared genetic bases 
of SCZ and BD with a panel of 28 CM traits. We performed Mendelian randomization (MR) to elucidate 
casual relationships between the two groups of disorders. We also identified the potential shared genetic 
variants by a statistical approach based on local true discovery rates, and inferred the pathways involved.  
 
Setting: The analysis was based on large-scale meta-analyses of genome-wide association studies (GWAS).  
 
Participants: GWAS data for SCZ and BD was taken from large meta-analyses (N=82315 and 40225 
respectively). We also included GWAS data from 28 CM traits, with total number of subjects exceeding a 
million.  
 
Main Outcomes and Measures: We found polygenic associations of SCZ with glucose metabolism 
abnormalities, adverse adipokine profiles, increased wait-hip ratio and raised visceral adiposity. However, 
BMI showed inverse genetic correlation and polygenic link with SCZ. On the other hand, we observed 
polygenic associations with an overall favorable CM profile in BD. MR analysis showed that SCZ may be 
causally linked to raised triglyceride and that lower fasting glucose may be linked to BD, although MR did not 
reveal other significant causal relationships in general. We also identified numerous SNPs and pathways 
shared between SCZ/BD with CM traits, some of which are related to inflammation or the immune system. 
 
Conclusions and Relevance:  
In conclusion, SCZ patients may be genetically associated with several CM abnormalities independent of 
medication side-effects, and proper surveillance and management of CV risk factors may be required from the 
onset of the disease. On the other hand, CM abnormalities in BD are more likely to be secondary.   
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Introduction  
Increased rates of cardiovascular diseases (CVD) have become a major area of concern for patients with 
schizophrenia (SCZ) or bipolar disorder (BD) 1,2. People with SCZ have a life expectancy around 15 to 20 
years shorter than the average population while the life expectancy for bipolar patients is 10 to 15 years 
shorter 3. The mortality ratio in SCZ and bipolar patients is about 2.5 to 3-fold as compared to the general 
population 4. Deaths from cardiovascular diseases have been proposed as a major contributor to the increased 
mortality 1,3. A 3-fold increase in CVD mortality was reported in patients with severe mental illness 
(schizophrenia-spectrum or bipolar disorders) aged 18-49 and a 2-fold increase in patients aged 50-75 5.  
  
The metabolic syndrome is a key risk factor for cardiovascular morbidity and mortality. It represents a 
cluster of metabolic abnormalities including dyslipidemia, impaired glucose tolerance, insulin resistance, 
hypertension and central obesity 6.  
 
A raised prevalence of metabolic syndrome has been observed in SCZ patients. In the CATIE study 7, the 
baseline prevalence of metabolic syndrome was 35% and 50% in males and female patients respectively. 
Mitchell et al. 8 conducted a large-scale meta-analysis comprising 25962 subjects and reported that metabolic 
syndrome is found in almost 1 out of 3 unselected SCZ patients. For BD, heightened risks of metabolic 
abnormalities have also been recognized. A recent meta-analysis 9 estimated that the overall rate of metabolic 
syndrome is 37.3%, which is significantly higher than the general population.  
 
The underlying causes for increased risk of metabolic disorders are not completely understood. It has been 
suggested that a variety of factors including tobacco smoking, physical inactivity, inadequate somatic 
health-care services, antipsychotic medications and underlying genetics may all contribute to the heightened 
metabolic risks 1. In particular, anti-psychotic medications and mood stabilizers have been established and are 
widely known as significant contributors to metabolic abnormalities10,11. Nevertheless, metabolic 
abnormalities have also been observed in SCZ patients who are drug-naïve. For example, drug-naïve patients 
were reported to show impaired glucose tolerance, raised fasting glucose levels and insulin resistance in 
several studies 12. Impaired glucose tolerance has also been observed in first-degree relatives of affected 
patients13. Recently a few meta-analyses14-16 have studied glucose abnormalities among first episode 
drug-naïve SCZ patients. All of them concluded that SCZ patients had significantly worse glucose profiles 
than controls. As for other metabolic abnormalities that have been studied, a recent meta-analysis reported 
elevated triglycerides in first-episode psychosis patients but lower low-density cholesterol (LDL) and total 
cholesterol (TC) in patients17. A thorough review of metabolic syndrome in drug-naïve and treated SCZ 
patients can be found in Chadda et al 12.  
 
Very few studies have investigated metabolic traits in drug-naïve bipolar patients and compared them to a 
control population. A recent study showed an increased rate of insulin resistance in these patients but there 
were no difference in the rate of metabolic syndrome18. We are not aware of any systematic review or 
4 
 
meta-analysis of cardiometabolic traits in bipolar patients.  
 
Previous individual studies are usually of small sample size (mostly less than 100 subjects), and often 
included only a subset of metabolic parameters. Although a few meta-analyses have been performed, the range 
of traits studied are limited (mainly glucose and lipid traits) and heterogeneity among different studies were 
inevitable. For example, there are often variability in inclusion and exclusion criteria. The duration of 
untreated psychosis were variable and not recorded in a number of studies. In some studies, patients may have 
received other psychotropic agents (e.g. mood stabilizer and antidepressants) that may affect metabolic 
profiles11,19. In other studies patients may have been prescribed antipsychotics for a short period of time 
(usually < 2 weeks)14. As a result, confounders such as psychiatric medications may still affect the results and 
it is hence difficult to confirm whether SCZ or BD itself is truly associated with CM abnormalities. As 
(germline) genetic variations are not affected by drugs, exploration of shared genetic bases may be more 
useful in discerning whether the disorders (SCZ/BD) themselves contribute to CM abnormalities in patients. 
Also, the current study included results large samples of patients, totaling over a million participants. As 
another limitation of prior studies, causal relationships between SCZ/BD and cardiometabolic traits are 
unclear, due to cross-sectional nature of many studies and other confounding factors.  
 
In view of limitations of previous works, further studies are warranted to investigate potential shared 
underlying pathophysiology of cardiometabolic traits with SCZ and BD. As both psychiatric and 
cardiometabolic traits are highly heritable 20,21, it is reasonable to suspect a shared genetic basis between them. 
In this study we investigated potential shared genetic predispositions by polygenic risk scores (PRS) and a 
two-dimensional version of the local true discovery rate (tdr) approach22. We also performed Mendelian 
randomization (MR) analysis to delineate whether there are any causal links among the two types of disorders.  
 
In a related work, Andreassen et al.23 proposed a conditional false discovery rate approach to identify loci 
associated with both SCZ and CVD risk factors, with an aim to improving gene discovery in SCZ. In the 
current work we took a different and more comprehensive approach. Compared to the study by Andreassen et 
al., we employed methodologies based on PRS and LD score regression to assess overall genetic sharing. We 
also studied the genetic sharing of cardiometabolic risks with BD, a topic not investigated before. In addition, 
a much wider range of metabolic parameters and diseases were included here, and the sample size of SCZ 
GWAS in this study reaches ~82000, about 4 times the size of the previous one24. Importantly, we also looked 
into the directions of associations in this study which was not addressed previously 23.  
 
The overall analytic workflow is briefly described as follows (Figure 1). Firstly, we made use of large-scale 
GWAS meta-analyses results for SCZ, BD and a comprehensive panel of 28 metabolic and cardiovascular 
traits to test for associations of polygenic scores. Linkage disequilibrium (LD) score regression was conducted 
as well. We also examined PRS associations with cardiovascular risk factors in the Northern Finland Birth 
Cohort with individual genotype and phenotype data. We then performed MR analysis to assess causal 
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relationship between the two groups of disorders. Finally, we “zoomed in” to discover the genetic variants 
shared between SCZ and BD with each metabolic trait, and inferred the likely involved pathways by gene-set 
analyses.  
 
To our knowledge, this is the first systemic and the most comprehensive study to date on the shared genetic 
bases of cardiometabolic traits with both SCZ and BD using PRS, and the first to uncover shared genetic 
variants between BD and cardiometabolic diseases with large-scale GWAS data. Except for a recent study 
which employed MR to study the relationship between BMI and psychiatric disorders25, we are unaware of 
other works studying causal links of SCZ/BD with CM traits. 
 
Materials and methods 
GWAS samples 
We derived PRS from summary statistics of GWAS meta-analyses. The summary results for SCZ 26 was based 
on a large-scale meta-analysis (N = 82315) obtained from the Psychiatric Genomics Consortium website 
(https://www.med.unc.edu/pgc). Summary statistics for BD was based on the study by Hou et al.27 (N = 40255) 
available from https://www.ebi.ac.uk/gwas/downloads/summary-statistics. We also obtained GWAS summary 
statistics for a range of CM traits, including low-density lipoprotein (LDL) (N = 89872), high-density 
lipoprotein (HDL) (N = 94294), total cholesterol (TC) (N = 94577), triglycerides (TG) (N = 90996) 28, body 
mass index (BMI) (N = 339224) 29, fasting glucose (FG) (N = 58074)30, fasting insulin (INS) (N = 51570)30, 
waist-hip ratio (WHR) (N = 144446)31, type 2 diabetes (two datasets, N = 110452 and 16580 respectively)32,33, 
coronary artery disease (CAD) (N = 184305)34, leptin (N = 32161)35, adiponectin (N = 45891)36, systolic and 
diastolic blood pressure (SBP/DBP) (N = 146562)37, body fat percentage (N = 100716)38, subcutaneous 
adipose tissue volume (SAT) (N = 18247), visceral adipose tissue volume (VAT) (N = 18332), pericardial fat 
volume (PAT) (N = 12204), subcutaneous adipose tissue attenuation (SATHU) (N = 12439), visceral adipose 
tissue attenuation (VATHU) (N = 12519) and VAT/SAT ratio (N = 18191)39. For FG, INS, WHR, leptin, VAT, 
VAT/SAT ratio, we obtained the summary statistics both with and without adjustment for BMI. For PAT, we 
included test statistics adjusted for height and weight. Details of individual studies are given in the above 
references. The summary statistics for blood pressure was taken from exome-based studies37 which provided 
the directions of associations. The other publicly available GWAS dataset on BP40 did not specify association 
directions. Summary statistics were downloaded via links in LD-hub (http://ldsc.broadinstitute.org/) or the 
GRASP webpage (https://grasp.nhlbi.nih.gov/FullResults.aspx).  
 
Derivation of polygenic risk scores (PRS) with summary statistics 
PRS can be formulated as a weighted sum of allelic counts, with the weights determined by the effect sizes 
of individual genetic variants. The PRS for an individual i (ri) can be denoted as 
i j ij
i
r w x  
where ijx is the (centered) allelic count for the jth SNP for the ith individual, jw  is the weight given to the 
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jth SNP, given by the log odds ratio or regression coefficient in a regression. We employed two approaches for 
PRS testing. In the first approach, only the summary statistics of each pair of traits are used. Association 
testing was carried out by the method “gtx” first described by Johnson 41. Details of this methodology was 
also described in several other studies42-44. The method tested for association of the PRS derived from the first 
trait (ri) with an outcome iy  (with values centered) by regression: i iy r , where  is the regression 
coefficient.   can be estimated by 
2
2 2
ˆ
j
j j j
i
j
i
w s
w s







     
and the standard error estimated by  
2 2
1
( )
j j
i
SE
w s




   
Here ˆ j  is the regression coefficient when the outcome iy  is regressed onto the jth SNP, and js is 
corresponding standard error of ˆ j . In order to investigate the bi-directional effects of polygenic risk of SCZ 
and BD on metabolic traits, we performed two sets of analyses, one using PRS from the psychiatric disorders 
to regress on metabolic traits and the other using PRS from metabolic traits to regress on SCZ or BD. The 
above formula is equivalent to the “inverse variance weighted” (IVW) approach in MR studies. However, in a 
polygenic score analysis we do not impose stringent inclusion criteria for genetic variants: we do not require 
the variants to be strongly associated with the disease and pleiotropic effects are allowed. 
 
Polygenic risk score testing in the Northern Finland Birth Cohort 1966 
In the second approach, PRS testing was performed on individual genotype and phenotype data in the 
Northern Finland Birth Cohort (NFBC) 1966. The raw genotype and phenotype data was accessed from 
dbGaP (accession number phs000276.v2.p1). The original study has passed all relevant ethnical approvals. All 
study subjects were recruited from Norther Finland and all traits in this study were measured at 31 years old. 
GWAS has been performed on this cohort using the Infinium 370cnvDuo array 45. We included a range of 
metabolic traits in our analyses, including TG, HDL, LDL, BMI, WHR, FG, INS, systolic blood pressure (SBP) 
and diastolic blood pressure (DBP).  
 
Standard GWAS quality control procedures were performed. Genetic variants with missing rate >10%, 
minor allele frequency <0.01 and with significant deviation from Hardy-Weinberg equilibrium (p<10-5) were 
excluded. Individuals with genotyping rates <90% were excluded from analyses. We also excluded individuals 
who are pregnant, receiving anti-diabetic medications, or not fasted before blood glucose and lipid 
measurements. After the above filtering and quality control procedures, 4982 individuals and 334458 SNPs 
were retained for further analyses.  
7 
 
 
Linear regression was carried out to test for the association of PRS with each of the metabolic traits. We 
included gender and the top ten principal components (PCs) derived from GWAS data as covariates 46. The 
analyses were repeated with and without BMI as a covariate. 
 
For both types of analyses (summary statistics and individual genotype-based) listed above, PRS analyses 
were performed by the R program PRsice 47. Linkage disequilibrium (LD) clumping was performed prior to 
polygenic scoring. This procedure preferentially selects markers with lower p-value while pruning out variants 
having a certain degree of LD with the selected ones. We used an R2 threshold of 0.25 for testing PRS 
associations in the NFBC sample. The method gtx however requires a stronger assumption on the 
independence between SNPs, and we chose an R2 threshold of 0.05, following the suggestions given in the 
PRsice vignette. We used the 1000 Genome Project sample as reference LD panel for gtx analyses. Polygenic 
scores were calculated over a range of p-value thresholds (0.001, 0.005, 0.01, 0.03, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5). 
 
  Most polygenic score analyses involved quantitative cardiometabolic traits. This approach avoids bias and 
false positive associations due to potential sample overlap. As shown by Burgess et al.48, Mendelian 
randomization studies (using a similar mathematical formulation as gtx) do not suffer from bias if risk factor 
measurements are made only in the control sample, even in a one-sample setting (i.e. 100% of controls 
contribute to the risk factor measurement). In our case, we have checked that all continuous cardiometabolic 
traits were not measured in SCZ or bipolar patients; and despite possible overlap in control subjects, the 
overlap is far less than 100%, hence the chance of false positive associations is low. To further check for 
sample overlap, we also examined the intercept from LD score regression49. We examined whether the 
intercept is significantly different from zero as an additional method of checking for overlap. (The intercept 
should be close to zero when there is no overlap in samples)49. As will be described in the results section, there 
is no evidence of significant overlap except for two case-control traits, DM and CAD. We also included 
another DM GWAS dataset derived from Japanese subjects to ensure the absence of overlap with SCZ/BD 
samples. 
 
Multiple testing was corrected by the false discovery rate (FDR) procedure, which controls for the expected 
proportion of false positives50. FDR was computed for each pair of traits, and as shown by Efron51, the overall 
FDR is also controlled at the same level. The R program p.adjust was used to compute the corresponding FDR 
for every hypothesis test, which is also known as the q-value (the proportion of null was set to be one in all 
calculations). A q-value smaller than 0.05 is regarded as significant while results with q-values between 0.05 
and 0.1 are considered suggestive associations.  
 
 
Cross-trait LD score regression (LDSC) 
Cross-trait LD score regression was performed to assess genetic correlations49. We employed the LDSC 
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program (available at https://github.com/bulik/ldsc) for the analysis, following default parameter settings. This 
approach allows for sample overlap and accounts for LD between markers. The program “popcorn”, which 
accounts for differing ethnic groups of samples, was used for LD score regression involving the Japanese DM 
sample52. As explained earlier, the significance of the cross-trait LDSC intercept was assessed by dividing the 
estimated intercept by its standard error. LD score regression was not conducted for SBP and DBP as these 
were exome-based studies and LDSC was not designed for such studies.  
 
Mendelian randomization (MR) analysis  
Next, we performed MR analysis to assess causal relationships between SCZ/BD with CM disorders. MR 
utilized genetic variants as “instruments” to represent the risk factor and analyzed the relationship with an 
outcome53,54. Intuitively, MR is analogous to a randomized controlled trial (RCT). For example, in an RCT of 
a LDL-lowering drug, patients are randomized to receiving the drug or placebo; similarly, in an MR study, 
patients with genetically lower LDL (as determined by one or multiple variants) are analogous to receiving the 
lipid-lowering drug. Due to the random allocation of alleles by Mendel’s second law, the process is 
“randomized”, and MR is sometimes known as the “nature’s RCT”. Compared to conventional observational 
studies, MR are less susceptible to confounding and reverse causality53,54.  
 
In the current study, we performed two-sample MR with GWAS summary statistics using the R package 
“MR-base”55. SNPs passing genome-wide significance (p < 5e-8) were selected as instruments for exposures. 
The SNPs are first LD-clumped following the default settings in MR-base (clumping window of 10000kb, R2 
threshold of 0.01). We conducted MR with three commonly used approaches, including the inverse-variance 
weighted (IVW)41,42,56, MR Egger57 and weighted median methods58. The latter two methods can be used to 
account for horizontal pleiotropy (i.e. the instrument genetic variant(s) affect the outcome via pathways other 
than through the exposure). The Egger method gives unbiased estimate of the causal effect in the presence of 
directional pleiotropy, under the assumption that the pleiotropic effects are independent of the genetic 
association with the risk factor (“InSIDE” assumption)57. The weighted median approach gives valid estimates 
when at least half of the information comes from valid instrumental variables58. We primarily reported the 
IVW estimates, however if Egger’s method reveal significant (unbalanced) horizontal pleiotropy, the latter 
two estimates are reported. We did not report the results for DM32 and CAD34 due to potential issues of 
overlap. 
 
Note that in polygenic score analyses horizontal pleiotropy is allowed but it will affect the validity of casual 
inference in MR. Polygenic score studies can elucidate shared genetic bases between disorders but is not 
designed for casual inference.  
 
Discovering shared SNPs  
For each pair of diseases (psychiatric versus metabolic), we computed for every SNP the probability of being 
associated with both diseases, given the observed test statistics. It can be viewed as a two-dimensional 
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extension of the local true discovery rate 59. The approach is closely related to the conditional false discovery 
rate 23 and a similar formulation has been proposed. However, our focus is on the probability of shared 
associations instead of chance of associations conditioned on another trait. The methodology we used here 
followed that proposed by Chung et al. 60, although we worked with the z-statistics instead of p-values. Briefly, 
we assumed a four-group mixture model of z-statistics:  
00 00 10 10 01 01 11 11( , ) ( , ) ( , ) ( , ) ( , )A B A B A B A B A Bf z z p f z z p f z z p f z z p f z z     ----(1) 
where zA and zB refer to the z-statistics of trait A and trait B respectively. For a genetic variant, it can be 
associated with none of the traits, with one trait only, or both. The four possibilities are modeled in the above 
equation following Chung et al60. For instance, p11 denotes the proportion of markers that has association with 
both traits, and f11 denotes the probability density function of the z-statistics of this group of markers. From 
equation (1) we can derive the probability that a SNP is associated with both traits (denoted by tdr11), using an 
expectation-maximization (EM) algorithm. Further details of the method are given in Supplementary 
Information. We also conducted the same analysis on CAD and DM and presented the results for reference, 
although sample overlap is present. This is because as the analysis is SNP-based, the effect of sample overlap 
will not be accumulative across variants as in a PRS analysis (PRS involves adding up the effects of a large 
number of variants); also, the ranks of shared genetic variants are unlikely to be affected even when there is 
overlap, since the correlations between samples influence each SNP in similar ways. Moreover, as shown in48, 
the bias due to overlap is inversely related with effect size of genetic variants. Since we only focus on the top 
shared SNPs, any bias due to overlap is likely to be small.  
 
Pathway analysis  
We selected SNPs with tdr11>= 0.5 and mapped those SNPs to genes using the Bioconductor package BioMart 
using default settings. We noted that some SNPs were mapped to multiple genes which may bias the results of 
gene set analyses. We adopted the following method to correct for this bias. We first extracted information on 
variant consequences (using sequence ontology [SO] terms) via BioMart. Each SNP was then mapped to the 
gene which corresponds to the highest impact rating (as listed in 
http://asia.ensembl.org/info/genome/variation/predicted_data.html#consequences). For example, for a SNP 
listed as a frameshift variant in gene A and an intron variant in gene B, the SNP is mapped to gene A only. The 
pathway analyses based on hypergeometric tests. We performed analyses by ConsensusPathDB, which 
integrates a variety of databases such as KEGG, Reactome, Wikipathways and BioCarta into a single resource. 
Analyses were separately carried out for variants having the same, opposite or either directions of associations 
with SCZ/BD and CM traits.  
 
Results  
SCZ and cardiometabolic traits 
The associations of SCZ with cardiometabolic traits using paired summary statistics are shown in Table 1. 
PRS were first constructed from SCZ GWAS data and CM traits were treated as the outcomes (i.e. target 
phenotypes). Then the analyses were repeated with PRS derived from CM traits. Intuitively, PRS from CM 
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traits can be regarded as a proxy of the actual level of the trait and a previous study 61 has shown that such a 
polygenic scoring approach can be used to test association of biomarkers with disease. For binary traits, the 
polygenic scores may be regarded as the underlying liability to the corresponding disorder.  
 
Overall the strongest association was observed for BMI (lowest p = 2.82E-12) in polygenic score analyses 
when SCZ was used either as the predictor or target phenotype. Interestingly, the coefficient was negative, 
signifying an inverse association. For lipid traits, we observed a positive polygenic association of SCZ with 
HDL, but no significant associations with LDL and TG. The polygenic association with LDL reached nominal 
significance (at the optimal p-value threshold), but did not pass the preset FDR threshold of 0.1. For the two 
adipokines on the list, we observed positive polygenic associations with leptin (BMI-adjusted) and inverse 
association with adipokine when SCZ PRS was used as the predictor variable. It is worth noting that both 
raised leptin and reduced adiponectin were associated with heightened CV risks62,63. As for measures of 
obesity and fat deposition (other than BMI), positive association with WHR was observed, especially for 
BMI-adjusted WHR. Positive association was also seen for BMI-adjusted visceral adiposity, although we 
observed a negative link of SCZ PRS with subcutaneous adipose tissue mass (unadjusted for BMI). Finally, 
for traits related to glucose metabolism, PRS of FG was positively associated with SCZ and similar 
association was observed for PRS derived from fasting insulin. In addition, we observed a positive polygenic 
link of SCZ PRS with type 2 DM. LD score regression revealed a significant genetic correlation of lower BMI 
with SCZ, although there were no other significant results. The intercepts from cross-trait LD score regression, 
which also served as a test for sample overlap, were largely non-significant. The exceptions included CAD 
and DM, which were expected due to overlap in control subjects. While another trait (adiponectin) also 
showed p < 0.05 for the LD score intercept, we expect (0.05*26) ~ one “false-positive” at an alpha level of 
0.05 (not counting CAD/DM), therefore the results were consistent with the absence of significant sample 
overlap affecting the results.  
 
  For analyses on the Northern Finland Birth Cohort, the most significant association was WHR adjusted for 
BMI (lowest p = 0.013, q = 0.055) (Supplementary Table 1). Other results were largely non-significant, 
probably owing to a much smaller sample size of NFBC compared to other GWAS meta-analyses.  
 
In the MR analysis (Table 3), when SCZ was considered as the risk factor, the most significant result was 
observed for TG. There was evidence of horizontal pleiotropy (p = 0.001), so we focused on results from 
Egger regression and the weighted median method. The Egger’s method suggested that SCZ may be causally 
related to an increase in TG (beta= 0.186 [95% CI: 0.093 – 0.279], p = 3.37E-4, q = 0.009) while the estimate 
from the weighted median approach showed a trend towards significance (p = 0.077). We also checked the test 
results for heterogeneity and found no significant heterogeneity for the MR Egger method (p = 0.208). We 
observed a nominally significant association with pericardial fat volume by the IVW approach, which was 
stronger after adjusting for BMI (beta= 0.072 [95% CI: 0.011 – 0.134], p = 0.021, q = 0.288), although both 
results did not pass the preset FDR threshold. We did not observe significant causal relationship with other 
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CM traits. When SCZ was regarded as the outcome and CM traits as risk factors, there was no evidence of 
causal relationships for any CM trait, except that insulin was weakly significant (beta = 1.066 [95% CI: 
0.040 – 2.091], p = 0.042) but did not pass FDR correction.  
 
The full results of the shared SNPs analyses with tdr11>0.5 are presented in Supplementary Table 5. We also 
present “gene-based” results for the top genes mapped to the shared SNPs (Supplementary Table 7). The top 3 
genes shared between SCZ/BD and each CM trait are shown in Table 5. Across all CM traits, we discovered in 
total 15422 and 2890 shared genetic loci with tdr11> 0.5 and >0.8 respectively (as determined by clumping at 
an R2 threshold of 0.1 using 250-kb windows; Supplementary Table 11). As ConsensusPathDB outputs 
enrichment results from numerous pathway databases, there was some overlap with similar pathways and 
involved genes. Also due to the very long list of pathways involved for different traits, we present selected top 
pathways in Table 6, taken from the top 25 most commonly top-ranked pathways across all traits (with 
reduced repetitions of similar pathways). The full results of pathway analyses are presented in Supplementary 
Table 9. We also presented summary results of pathways derived from SNPs having the same direction of 
associations with CM disorders, given the polygenic association of SCZ with worse CM risks with regards to 
several metabolic parameters.  
 
Bipolar disorder and cardiometabolic traits 
Table 2 shows the polygenic associations of BD with cardiometabolic traits using paired summary statistics. 
Similar to SCZ, we observed an inverse association with BMI (p = 9.34E-13) when BD was treated as the 
target or base phenotype. We also observed a polygenic association of lower WHR with BD (p = 1.35E-03), 
but the result became non-significant after adjustment by BMI, suggesting the original association is mainly 
driven by BMI. For lipid traits, we observed polygenic associations of BD with higher HDL, as well as lower 
LDL, TC and TG. We also detected polygenic associations with lower leptin levels and SBP.  
 
In LD score regression, none of the genetic correlations achieved q-value < 0.1 but a number of traits were 
nominally significant with q < 0.2. These included BMI and WHR, which showed negative genetic 
correlations with BD, consistent with results from the PRS analysis. Fasting glucose and insulin showed 
nominally significant negative genetic correlations with BD. Interestingly, we observed a marginally 
significant positive correlation with DM. The overall direction of genetic correlations from LD score analysis 
leaned towards lower CM risks, broadly in line with PRS analyses. The LD score regression intercepts were 
again mostly non-significant apart from CAD and DM.  
 
As for the analyses of the NFBC cohort, we did not observe any significant results passing FDR correction 
(Supplementary Table 2). Again the absence of significant associations may be due to the relatively small 
sample size of NFBC cohort compared to other GWAS meta-analyses. Nevertheless, for a few traits showing 
at least p<0.05 at the optimal p-value threshold (including INS, TG and SBP), the directions of associations 
were negative, largely in line with the summary PRS and LD score analyses.  
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In the MR analysis (Table 4), when BD was treated as the exposure, there was no evidence of casual 
relationship with CM traits. On the other hand, when CM traits were considered as exposures, we observed 
several nominally significant results. For example, lower FG appeared to be casually related to BD (beta = 
-4.474, SE = 0.183, p = 0.01). Results for SBP and WHR (BMI adjusted) were only nominally significant but 
did not pass FDR correction. The association with BMI was statistically significant based on Egger’s approach, 
but there was significant heterogeneity among the casual effects of individual variants (p = 0.022). This may 
reflect the genetic instruments were measuring different quantities, casting doubt on the assumption of MR 
being valid for all genetic variants. We did not observe evidence of heterogeneity for other nominally 
significant results.  
 
The results of the shared SNPs analyses are presented in Supplementary Tables 6 and 8, the latter showing 
genes mapped to the top shared SNPs. Across all CM traits, we found totally 3115 and 297 shared genetic loci 
with tdr11> 0.5 and >0.8 respectively (after clumping the original results at an R2 threshold of 0.1; see 
Supplementary Table 11). As GWAS sample size for BD is smaller, the number of shared SNPs with high tdr11 
was smaller. Selected top pathways are given in Table 6 while Supplementary Table 10 shows the full results 
of gene-set enrichment analysis.  
 
Discussion 
In the current study, we have performed polygenic risk score analyses on the possible shared genetic basis of 
SCZ and BD with a comprehensive panel of cardiometabolic traits. We observed a number of potential 
polygenic associations, which will be discussed below.  
 
SCZ and cardiometabolic traits 
Raised cardiovascular morbidity and mortality is well-established in SCZ, yet it is difficult to disentangle the 
numerous possible underlying factors, including the side-effects of antipsychotics. Broadly in line with 
previous studies, we observed here a positive polygenic association of higher FG with SCZ. Similarly, a 
positive polygenic link of SCZ with DM was detected. It is notable that multiple studies have found impaired 
glucose tolerance or insulin resistance in drug-naïve patients and their first-degree relatives 13-16,64-69.  
 
  Despite increased cardiovascular risks in SCZ patients, surprisingly, we found evidence for an inverse 
relationship between polygenic scores of BMI and SCZ. Interestingly, a population cohort study of over one 
million men in Sweden also reported that subjects with lower BMI had an increased risk of developing SCZ 70. 
A similar study in Denmark reached the same conclusions 71. A few studies in drug-naïve patients also 
revealed a trend of lower BMI. For instance, lower BMI among drug-free SCZ patients was reported by 
Spelman et al. 13 and Pandmavati et al. 72. However, some studies failed to detect any differences in BMI 
between SCZ cases and controls 64,65. The underlying pathophysiology for an inverse relationship between 
BMI and SCZ is unknown. One hypothesis is that poor nutritional status, however subtle, may adversely 
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affect neural development 70 which leads to psychotic disorders.  
 
  While we observed that lower BMI polygenic score is associated with SCZ and vice versa, we observed the 
opposite trend for WHR. Polygenic association of higher WHR with SCZ, especially after adjustment for BMI, 
is shown both in the Northern Finland cohort sample and analyses using summary statistics. Moreover, this 
study revealed potential polygenic link of SCZ with increased visceral adiposity, and an unfavorable profile of 
adipokines (raised leptin and decreased adiponectin). Consistent with this finding, Ryan et al. reported higher 
WHR and three times more intra-abdominal fat in drug-free SCZ patients compared to BMI-matched controls 
73. Others74 75 also reported increased WHR in drug-free patients compared to controls. While some studies did 
not find any differences in WHR64,76, they were of small sample sizes and inadequate power may explain the 
inconsistent results. Waist-hip ratio reflects visceral fat deposition, and has been suggested to be an 
informative predictor of cardiovascular risks independent of BMI77,78. As for adipokine abnormalities, a recent 
meta-analyses reported elevated leptin levels in SCZ patients, although the increase was moderate79. However, 
many studies in the meta-analyses involved patients taking antipsychotics, and for those studies on 
antipsychotic-naïve patients, the sample sizes were small. With regards to adiponectin, meta-analysis showed 
that SCZ patients taking second-generation antipsychotics (SGAs), especially clozapine and olanzapine, had 
significantly lower adiponectin levels80. Here we showed that SCZ patients may be genetically associated with 
adverse adipokine profiles (which are linked to raised CV risks), independent of antipsychotic effects.  
 
For lipid traits, we observed polygenic associations with higher HDL levels. The associations with LDL and 
TC were not significant but the directions were negative (and nominal significance was reached if only the 
best p-value threshold was considered), consistent with a favorable cholesterol profile. However, in the MR 
analysis, SCZ appeared to be causally associated with increased TG. These findings were generally consistent 
with a very recent meta-analysis17 on lipid profiles in first-episode psychosis patients which reported higher 
TG but favorable cholesterol profiles among patients, although they did not reveal changes in HDL.  
 
  In general, we did not find evidence for causal relationship between SCZ and CM traits, with the exception 
of TG. This suggests that SCZ per se may not directly cause changes in CM traits; the associations of SCZ (as 
a disease itself, without considering medication side-effects) with CM abnormalities are more likely due to 
shared genetic or environmental risk factors. In other words, similar risk factors may influence the risks of 
both SCZ and CM disorders together, but through different pathways. The shared genetic factors are addressed 
in this study but some previous studies also suggested shared environmental factors for the two kinds of 
disorders. For example, both SCZ and DM may be associated with risk factors during early development, such 
as low birth weight and maternal malnutrition81,82. For example, individuals conceived or in early gestation 
during famines are more likely to develop both SCZ and type 2 DM83,84.  
 
Bipolar disorder and cardiometabolic traits  
Similar to SCZ, we observed an inverse genetic relationship between BMI and BD. One previous clinical 
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study reported a higher prevalence of being overweight among bipolar patients 85. However, the weight 
measurements were not made during euthymic period and 71.4% of the patients were depressed during the 
measurement. It is possible that the symptoms of bipolar depression contributed to the findings. As remarked 
by the authors, their findings might be more related to the current episode of illness than to the underlying 
disorder 85. Also the comparison group was patients with obsessive-compulsive disorder, not healthy 
population controls. While WHR was also inversely related to BD in the unadjusted analysis, the relationship 
no longer exists after controlling for BMI.  
 
  There are very few studies on the metabolic parameters in drug-naive bipolar patients in comparison with 
healthy controls. We do not observe evidence of polygenic association of hyperlipidemia with BD; on the 
contrary, there appeared to be an inverse relationship with LDL, TC and TG. This result could be confounded 
by BMI, although studies have found lower cholesterol level in bipolar patients 86,87. There is also evidence of 
a correlation between low cholesterol levels and suicide risks 88. The underlying mechanism remains elusive, 
but it has been suggested that low cholesterol may be associated with decreased lipid microviscosity in neural 
membranes and reduced exposure of serotonin receptors on membrane surface. Serotonergic dysfunction may 
in turn contribute to suicidality 89. Overall we observed polygenic associations of BD with favorable metabolic 
parameters, suggesting that other secondary risk factors (e.g. medications) may play a larger part than the 
disorder itself in affecting cardiovascular risks. One exception is that the genetic correlation with DM was 
positive, although the correlations with fasting glucose and insulin were negative. One possibility is that some 
findings may represent false positives, given that they were only nominally significant and did not pass our 
preset q-value threshold. Another explanation is that the study on fasting glucose and insulin was performed 
on non-diabetic subjects30, and genetic factors associated with normal-range glucose levels may not fully 
overlap with the variants conferring susceptibility to frank diabetes90,91.  
 
As for the results from MR analysis, there was no evidence of causal relationships when BD was treated as 
the exposure. When BD was considered as the outcome, lower FG appeared to be casually linked to BD. We 
are not clear about the underlying mechanisms, but interestingly a recent study reported greater mood lability 
being associated with lower fasting glucose levels92. However, yet another small-scale study patients revealed 
more glucose abnormalities in drug-naïve bipolar patients18. Further clinical studies are required to elucidate 
the exact relationship. Other MR results did not pass FDR correction, and for BMI there was high 
heterogeneity which cast doubt on the validity of the instruments.  
 
 
Clinical implications  
Our findings provide evidence to support increased awareness and better monitoring and management of CV 
risks in psychosis patients, especially for SCZ. Taken together, we found evidence of polygenic associations 
with glucose metabolism abnormalities, adverse adipokine profiles, central obesity and increased visceral 
adiposity in SCZ. These findings are grossly in line with observations from epidemiological studies. If our 
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findings are validated in further studies, given that SCZ patients may be associated with several CM 
abnormalities independent of medication side-effects, proper surveillance and management of CV risk factors 
may be required from the onset of the disease, and even in patients who are taking drugs with less metabolic 
side-effects or low-dose medications. Our findings also suggest that the measurement of WHR (instead of 
BMI alone) may be useful in screening for metabolic risks, due to its closer association with visceral adiposity. 
Also, adipokines such as leptin and adiponectin may warrant further investigations as biomarkers for CV risks 
in SCZ patients.  
 
  On the other hand, we observed polygenic associations with favorable cholesterol profiles in SCZ and BD, 
and an overall favorable CM profile in BD patients. These results suggest that hypercholesterolemia in SCZ 
and many CM abnormalities in BD may be secondary (and hence more readily modifiable) instead of being 
related to the underlying pathophysiology of SCZ/BD. One of the most important risk factor would be 
side-effects from antipsychotics and mood stabilizers; careful choice and dosing of these drugs will likely 
reduce CV risks in such patients. Promotion of healthy lifestyle (e.g. proper diet and exercise) might also be 
beneficial to SCZ/BD patients.  
 
Shared SNP analyses of SCZ and bipolar disorder with cardiometabolic traits 
We identified a number of susceptibility variants that are potentially shared between SCZ or BD and 
cardiometabolic traits. As the list is long, we will not discuss each susceptibility gene in detail but will 
highlight a few associated pathways here. For example, it is interesting to note that pathways associated with 
immune functioning (e.g. antigen processing, complement pathways) were ranked highly among a number of 
cardiometabolic traits, such as HDL, LDL, TG, DBP and WHR, and such pathways were ranked high in both 
SCZ and BD. If we limit our analyses to shared SNPs with the same directions of effects on SCZ and CM 
risks, the pathway most frequently listed was antigen processing and presentation, which was listed as a 
significant pathway in 7 metabolic traits. Immune system dysfunction has been implicated in SCZ, BD 93 as 
well as cardiometabolic traits 94. Recent studies have suggested that chronic inflammation may be an 
important mediator linking metabolic abnormalities and severe mental illnesses 95. For example, elevations of 
pro-inflammatory cytokines such as tumor necrosis factor alpha and interleukin-6 have been observed both in 
patients with psychosis and metabolic syndrome. Chronic systemic inflammation may be coupled with 
microglia activation in the brain, which may disturb neuronal functions 95. On the other hand, inflammation 
occurring in visceral adipose tissues, the liver, pancreatic islets and blood vessels contribute to metabolic 
abnormalities and atherosclerosis 96. Our findings support a potential role of inflammation and immune system 
pathways in the shared genetic bases of SCZ and BD with cardiometabolic abnormalities. In addition, we also 
observed that lipid metabolism and the statin pathway were among the pathways most often implicated. 
Statins have been known to lower the risk of coronary artery disease 97, yet it has also been investigated as 
adjunctive therapy for SCZ 98. Vincenzi et al. 98 observed a significant decrease in positive symptoms of SCZ 
patients from baseline to 6 weeks with pravastatin treatment, though the decrease was not significant at 12 
weeks. It was postulated that the anti-inflammatory actions of statin contributed to the therapeutic effect on 
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SCZ. It is worthwhile to note that the anti-inflammatory potential of statins has been postulated as a chief 
mechanism responsible for preventing CAD 99 as well. Another pathway listed was EGFR-1 signaling 
pathway, which was implicated in multiple facets of cardiovascular abnormalities, such as endothelial 
dysfunction and atherosclerosis (reviewed in ref.100). The EGF family and related proteins such as ErbB1-4 
also serve important functions in brain functions and pathology of SCZ101.  
 
Study limitations 
There are a few limitations to our study. Our analyses are based on large-scale GWAS meta-analyses results, 
but most studies were done in Caucasians. It is worthwhile to extend the study to other ethnic groups. For 
analyses using paired summary results, we were unable to control for other clinical factors, for instance 
adjusting for WHR or BMI when studying lipid traits. Further clinical studies of metabolic abnormalities in 
SCZ and bipolar patients, coupled with genetic testing, will be useful in delineating the susceptibility markers 
and providing more solid evidence of shared genetic susceptibilities. We have employed two different 
approaches, PRS analyses and LD score regression, to assess shared genetic bases between SCZ/BD and CM 
traits. However, each method has its limitations. For instance, it is relatively difficult to account for LD and 
sample overlap in PRS analyses. Although LD score regression takes into account these factors, it relies on 
other assumptions, for example it assumes that the casual variants are randomly distributed in the genome 
regardless of the LD structure, and that (ideally) the SNP effects are of equal variances (i.e. rare SNPs should 
have larger effect sizes and vice versa, such that the variance explained should be the same for each SNP)49,102. 
Deviation of effect sizes from normality may also render the procedure inefficient49. While it was shown that 
these assumptions may not influence the results much under moderate violations, it is unclear how these 
assumptions may fit for different diseases with diverse genetic architecture. The difference in the underlying 
methodology and assumptions may explain why PRS and LDSC results sometimes do not agree with each 
other. In addition, both methods as well as MR assume linearity of SNP effects. Also, SCZ and BD are likely 
to be heterogeneous disorders, and the association with CM abnormalities may differ within different patient 
subgroups.  
 
While we have discussed a few pathways that may be involved in the shared pathophysiology, further 
experimental studies are required to elucidate the exact mechanisms involved. Many other shared SNPs and 
pathways also warrant further investigations. Interestingly, we did not find uniformly increased polygenic 
risks of all metabolic abnormalities in SCZ and BD. Further investigations into the complex links between 
CVD risk factors and SCZ and BD might shed light on new therapeutic measures for both types of disorders.  
 
Figure legends 
Figure 1:  The overall analytic workflow. First, we made use of large-scale GWAS meta-analyses results for 
SCZ, BD and a comprehensive panel of 28 metabolic and cardiovascular traits to test for shared genetic bases 
by polygenic risk scores (PRS) and LD score regression. We also examined PRS associations with 
cardiovascular risk factors in the Northern Finland Birth Cohort with individual genotype and phenotype data. 
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We then performed MR analysis to assess causal relationship between the two groups of disorders. Finally, we 
“zoomed in” to discover the genetic variants shared between SCZ and BD with each metabolic trait, and 
inferred the likely involved pathways by gene-set analyses.  
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Table 1  Polygenic association testing of SCZ with cardiometabolic traits using summary statistics 
  Polygenic score analysis LD Score 
  SCZ as target SCZ as base     
  best_p pval coef qvalue best_p pval coef qvalue rg p qval 
Adiponectin 0.05 7.87E-02 -4.82E-03 3.97E-01 0.4 1.62E-03 -3.03E-03 6.92E-03 -0.002 0.967 0.968 
BMI 0.05 2.82E-12 -6.18E-02 1.67E-11 0.03 1.22E-10 -6.40E-03 1.22E-09 -0.068 0.006 0.157 
CAD                 -0.025 0.375 0.828 
DBP 0.03 2.42E-01 2.62E-03 8.56E-01 0.5 1.32E-01 -3.44E-02 5.60E-01       
DM                 -0.033 0.387 0.828 
DM-2ndset 0.3 7.74E-02 3.00E-03 3.43E-01 0.5 2.99E-03 2.03E-02 2.13E-02 0.067 0.096 0.705 
Fat-percentage 0.2 1.65E-02 4.42E-03 9.52E-02 0.1 1.93E-01 1.65E-03 6.29E-01 -0.016 0.601 0.843 
FG 0.05 1.28E-02 1.11E-02 4.67E-02 0.001 1.17E-01 -2.21E-03 3.16E-01 -0.029 0.383 0.828 
FG-adjBMI 0.005 7.48E-02 1.53E-02 2.63E-01 0.001 7.85E-02 -2.55E-03 3.57E-01 -0.021 0.537 0.843 
HDL 0.2 8.83E-04 1.74E-02 3.36E-03 0.01 7.23E-07 7.26E-03 6.27E-06 0.046 0.165 0.705 
INS 0.005 5.50E-03 2.06E-02 5.50E-02 0.03 5.41E-02 -1.65E-03 5.41E-01 0.013 0.789 0.888 
INS-adjBMI 0.005 3.64E-02 1.73E-02 3.56E-01 0.03 4.84E-02 -1.44E-03 4.68E-01 0.015 0.783 0.888 
LDL 0.1 1.26E-02 -1.33E-02 1.26E-01 0.05 4.73E-02 -2.54E-03 1.81E-01 -0.025 0.442 0.828 
Leptin 0.001 6.92E-03 4.09E-02 6.92E-02 0.1 2.86E-02 3.27E-03 1.55E-01 0.069 0.140 0.705 
Leptin-adjBMI 0.5 1.95E-02 1.03E-02 1.83E-01 0.005 5.86E-03 4.80E-03 3.28E-02 0.092 0.060 0.705 
PAT 0.5 3.55E-02 -3.34E-03 1.25E-01 0.05 4.03E-01 -2.74E-03 8.99E-01 0.053 0.460 0.828 
PAT-adjHtWt 0.4 5.42E-01 -9.70E-04 9.47E-01 0.001 1.84E-01 7.88E-03 9.64E-01 0.054 0.352 0.828 
SAT 0.03 4.02E-02 -5.11E-03 2.27E-01 0.03 5.84E-03 -7.60E-03 3.72E-02 -0.026 0.596 0.843 
SATHU 0.2 2.92E-01 -2.06E-03 8.96E-01 0.5 4.55E-01 -1.89E-03 9.87E-01 -0.210 0.209 0.705 
SBP 0.2 9.95E-02 -1.15E-03 6.04E-01 0.01 7.05E-03 -1.59E-01 7.05E-02       
TC 0.3 4.27E-02 -9.38E-03 1.99E-01 0.03 2.92E-01 -1.40E-03 8.39E-01 -0.023 0.422 0.828 
TG 0.3 8.80E-02 -8.71E-03 3.33E-01 0.001 1.83E-01 2.70E-03 9.76E-01 -0.043 0.142 0.705 
VAT 0.001 2.64E-02 1.56E-02 2.64E-01 0.005 3.47E-02 -7.60E-03 3.47E-01 0.005 0.934 0.968 
VAT-adjBMI 0.1 1.12E-03 6.50E-03 1.12E-02 0.5 5.50E-03 5.94E-03 3.52E-02 0.027 0.625 0.843 
VATHU 0.001 1.08E-02 -2.01E-02 1.08E-01 0.5 2.86E-01 -2.68E-03 7.79E-01 -0.030 0.670 0.862 
VATSAT 0.005 2.66E-01 4.58E-03 9.08E-01 0.005 1.39E-01 -5.35E-03 7.29E-01 0.033 0.549 0.843 
VATSAT-adjBMI 0.1 5.12E-01 -1.33E-03 8.43E-01 0.005 1.54E-01 -5.15E-03 9.42E-01 0.019 0.744 0.888 
WHR 0.5 3.75E-02 1.10E-02 3.43E-01 0.3 2.87E-02 1.95E-03 1.02E-01 -0.032 0.203 0.705 
WHR-adjBMI 0.2 1.91E-04 2.11E-02 1.50E-03 0.5 3.91E-05 3.63E-03 1.92E-04 -0.001 0.968 0.968 
SCZ was treated as the target phenotype (i.e. dependent variable) on the left block and treated as the base phenotype (i.e. as predictor variable) in 
the middle block. Best p, best p-value threshold; coef, regression coefficient; rg, genetic correlation.  
BMI, body mass index; CAD, coronary artery disease; DM, type 2 diabetes mellitus (sample mainly from Caucasians); DM-2nd set, type 2 diabetes 
(sample from Japanese); FG, fasting glucose; FG.adjBMI, fasting glucose adjusted for BMI; INS, fasting insulin; INS.adjBMI, fasting insulin 
adjusted for BMI; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides; TC, total cholesterol; WHR, waist-hip ratio; 
WHR.adjBMI, waist-hip ratio adjusted for BMI; SBP and DBP, systolic and diastolic blood pressure; SAT, subcutaneous adipose tissue volume; 
VAT, visceral adipose tissue volume; PAT, pericardial fat volume; SATHU, subcutaneous adipose tissue attenuation; VATHU, visceral adipose 
tissue attenuation; adjHtWt, adjusted for height and weight.  
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For PRS analyses, q-values < 0.05 are in bold while suggestive associations (0.05 <= q <= 0.1) are italics. For LD score regression, results with 
nominal significance (p < 0.05) are highlighted in bold.  
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Table 2  Polygenic association testing of bipolar disorder with cardiometabolic traits using summary statistics 
  BD as target BD as base   LD score   
  best_p pval coef qvalue best_p pval coef qvalue rg p qval 
Adiponectin 0.005 1.05E-01 -1.78E-02 3.90E-01 0.2 5.92E-02 -1.01E-03 2.16E-01 -0.026 0.741 0.770 
BMI 0.2 3.54E-11 -9.23E-02 3.54E-10 0.2 7.30E-06 -1.96E-03 3.47E-05 -0.094 0.014 0.127 
CAD                 0.017 0.652 0.765 
DBP 0.4 6.36E-01 -5.01E-04 8.78E-01 0.2 4.00E-02 -2.82E-02 4.00E-01       
DM                 0.112 0.043 0.151 
DM-2ndset 0.4 3.06E-02 -7.63E-03 1.61E-01 0.5 2.40E-02 -7.34E-03 1.41E-01 -0.053 0.415 0.717 
Fat-percentage 0.001 1.50E-02 -2.60E-02 1.50E-01 0.3 5.99E-03 -1.68E-03 2.66E-02 -0.076 0.147 0.362 
FG 0.001 4.14E-02 -6.00E-02 4.14E-01 0.005 5.59E-02 -1.55E-03 5.59E-01 -0.121 0.044 0.151 
FG-adjBMI 0.005 1.04E-01 -2.87E-02 7.08E-01 0.005 1.52E-02 -2.02E-03 1.28E-01 -0.140 0.015 0.127 
HDL 0.03 2.51E-06 7.64E-02 2.51E-05 0.3 2.01E-09 3.22E-03 2.01E-08 0.091 0.084 0.226 
INS 0.005 2.16E-02 3.62E-02 2.16E-01 0.2 3.17E-02 -8.07E-04 1.16E-01 -0.152 0.039 0.151 
INS-adjBMI 0.3 2.95E-02 -1.63E-02 1.03E-01 0.01 2.49E-02 -1.31E-03 1.20E-01 -0.155 0.019 0.127 
LDL 0.4 8.94E-05 -3.74E-02 5.41E-04 0.3 5.49E-03 -1.62E-03 2.53E-02 -0.020 0.708 0.765 
Leptin 0.03 1.37E-02 -3.51E-02 1.37E-01 0.05 3.94E-03 -2.11E-03 2.24E-02 -0.047 0.540 0.717 
Leptin-adjBMI 0.03 3.13E-02 -2.38E-02 1.08E-01 0.5 1.50E-03 -2.24E-03 6.43E-03 -0.032 0.685 0.765 
PAT 0.01 5.62E-02 1.27E-02 3.38E-01 0.01 2.19E-01 -3.40E-03 9.86E-01 0.102 0.364 0.717 
PAT-adjHtWt 0.005 1.63E-01 -1.11E-02 4.87E-01 0.01 3.31E-01 -2.70E-03 9.96E-01 0.056 0.553 0.717 
SAT 0.05 2.22E-01 5.90E-03 7.71E-01 0.005 4.15E-01 -2.17E-03 9.99E-01 0.018 0.799 0.799 
SATHU 0.01 2.46E-01 -9.03E-03 9.35E-01 0.001 4.72E-02 1.04E-02 2.98E-01 -0.130 0.395 0.717 
SBP 0.5 4.06E-01 -7.15E-04 9.41E-01 0.2 8.63E-05 -8.72E-02 8.63E-04       
TC 0.3 1.02E-02 -2.53E-02 3.27E-02 0.05 1.83E-02 -1.74E-03 1.83E-01 -0.108 0.045 0.151 
TG 0.4 8.53E-03 -2.79E-02 3.96E-02 0.05 2.47E-04 -2.50E-03 2.33E-03 -0.029 0.554 0.717 
VAT 0.5 1.03E-01 -6.22E-03 3.44E-01 0.2 2.38E-01 -1.40E-03 7.38E-01 -0.048 0.551 0.717 
VAT-adjBMI 0.001 2.33E-02 -3.38E-02 2.33E-01 0.2 6.04E-02 -2.23E-03 2.72E-01 -0.084 0.285 0.641 
VATHU 0.5 3.44E-01 3.72E-03 9.39E-01 0.2 3.58E-01 1.27E-03 8.33E-01 0.081 0.431 0.717 
VATSAT 0.5 1.55E-01 -5.38E-03 5.14E-01 0.5 1.13E-01 -1.76E-03 3.30E-01 -0.034 0.672 0.765 
VATSAT-adjBMI 0.5 2.48E-02 -8.48E-03 1.60E-01 0.5 1.11E-01 -1.77E-03 3.94E-01 -0.048 0.558 0.717 
WHR 0.001 6.34E-04 -1.64E-01 6.34E-03 0.001 2.72E-03 -5.28E-03 2.21E-02 -0.113 0.005 0.127 
WHR-adjBMI 0.005 5.49E-02 -5.82E-02 4.32E-01 0.001 1.63E-01 -2.48E-03 7.93E-01 -0.078 0.068 0.205 
 
Bipolar disorder was treated as the target phenotype (i.e. dependent variable) on the left block and treated as the base 
phenotype (i.e. as predictor variable) in the middle block. Best p, best p-value threshold; coef, regression coefficient. Please 
refer to the legends of Table 1 for other abbreviations.  
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Table 3    Mendelian randomization analysis of SCZ with cardiometabolic traits 
  SCZ as exposure      SCZ as outcome 
b se pval qval 
 
b se pval qval 
Adiponectin 0.001 0.013 0.964  0.970 
 
Adiponectin 0.008 0.108 0.941 0.941 
BMI -0.019 0.013 0.148  0.691 
 
BMI 0.044 0.111 0.694 0.941 
DBP -0.179 0.457 0.696  0.970 
 
DBP 0.007 0.019 0.725 0.941 
Fat-percentage -0.002 0.013 0.893  0.970 
 
Fat-percentage 0.207 0.121 0.088 0.475 
FG -0.001 0.009 0.877  0.970 
 
FG -0.049 0.116 0.674 0.941 
FG-adjBMI 0.000 0.009 0.970  0.970 
 
FG-adjBMI -0.191 0.106 0.071 0.475 
HDL 0.023 0.024 0.332  0.970 
 
HDL 0.031 0.041 0.458 0.941 
INS 0.004 0.007 0.597  0.970  INS 1.066 0.523 0.042 0.475 
INS-adjBMI 0.006 0.007 0.416  0.970 
 
INS-adjBMI 0.131 0.423 0.756 0.941 
DM-2ndset -0.062 0.104 0.553  0.970 
 
DM-2ndset -0.009 0.022 0.678 0.941 
LDL 0.008 0.013 0.534  0.970 
 
LDL 0.005 0.028 0.871 0.941 
Leptin -0.016 0.015 0.304  0.970 
 
PAT -0.029 0.084 0.732 0.941 
Leptin-adjBMI -0.005 0.012 0.685  0.970 
 
PAT-adjHtWt -0.059 0.060 0.328 0.941 
PAT 0.060 0.030 0.047  0.443 
 
SBP -0.002 0.013 0.902 0.941 
PAT-adjHtWt 0.072 0.031 0.021  0.288 
 
TC -0.003 0.031 0.921 0.941 
SAT 0.002 0.023 0.925  0.970 
 
TG 0.017 0.043 0.695 0.941 
SATHU 0.011 0.029 0.704  0.970 
 
VATSAT 0.264 0.158 0.095 0.475 
SBP 0.259 0.605 0.669  0.970 
 
VATSAT-adjBMI 0.163 0.135 0.230 0.920 
TC 0.023 0.015 0.114  0.637 
 
WHR -0.008 0.104 0.940 0.941 
TG* 0.186 0.048 3.37E-04 0.009 
 
WHR-adjBMI -0.032 0.100 0.752 0.941 
VAT -0.015 0.023 0.528  0.970 
      
VAT-adjBMI -0.004 0.023 0.850  0.970 
      
VATHU 0.002 0.030 0.946  0.970 
      
VATSAT -0.005 0.023 0.837  0.970 
      
VATSAT-adjBMI -0.001 0.023 0.956  0.970 
      
WHR 0.007 0.013 0.605  0.970 
      
WHR-adjBMI 0.016 0.014 0.255  0.970 
      
b: coefficient estimate from Mendelian randomization; se, standard error; pval, p-value; qval, q-value.  
*MR results for TG was taken from Egger's method as there was significant (unbalanced) horizontal pleiotropy (p = 0.001). Several traits 
do not have SNPs passing genome-wide significance which also overlap with the SCZ GWAS SNPs, and hence are excluded here. Due to 
sample overlap between CAD and DM (Caucasian sample) with SCZ/BD, these traits are not included in the MR analysis here. P-values 
and q-values < 0.05 are in bold.  
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Table 4   Mendelian randomization analysis of bipolar disorder with cardiometabolic traits 
  BD as exposure     BD as outcome 
b se pval qval 
 
b se pval qval 
Adiponectin 0.015 0.013 0.252 0.913 
 
Adiponectin -0.115 0.164 0.483 0.610 
BMI 0.007 0.023 0.748 0.913 
 
BMI*^ 0.984 0.374 0.010 0.067 
Fat-percentage 0.019 0.024 0.410 0.913 
 
DBP 0.044 0.023 0.054 0.148 
FG -0.004 0.009 0.638 0.913 
 
Fat-percentage 0.479 0.253 0.059 0.148 
FG-adjBMI -0.007 0.009 0.454 0.913 
 
FG -0.474 0.183 0.010 0.067 
HDL 0.009 0.016 0.585 0.913 
 
FG-adjBMI -0.505 0.174 0.004 0.067 
INS -0.003 0.009 0.745 0.913  HDL 0.071 0.064 0.266 0.443 
INS-adjBMI -0.009 0.008 0.257 0.913 
 
INS -0.997 0.733 0.174 0.316 
LDL -0.017 0.018 0.367 0.913 
 
INS-adjBMI -0.572 0.597 0.338 0.520 
Leptin -0.004 0.030 0.902 0.980 
 
DM-2ndset -0.051 0.034 0.133 0.266 
Leptin-adjBMI 0.000 0.026 0.994 0.994 
 
LDL -0.001 0.057 0.980 0.980 
PAT -0.010 0.039 0.789 0.913 
 
PAT -0.065 0.174 0.710 0.747 
PAT-adjHtWt -0.028 0.039 0.476 0.913 
 
PAT-adjHtWt -0.077 0.127 0.542 0.610 
SAT 0.036 0.030 0.232 0.913 
 
SBP 0.024 0.010 0.021 0.105 
SATHU -0.020 0.053 0.713 0.913 
 
TC* 0.006 0.061 0.127 0.266 
TC -0.020 0.018 0.264 0.913 
 
TG -0.046 0.077 0.549 0.610 
TG -0.008 0.016 0.607 0.913 
 
VATSAT 0.195 0.244 0.424 0.606 
VAT 0.019 0.040 0.635 0.913 
 
VATSAT-adjBMI 0.127 0.198 0.522 0.610 
VAT-adjBMI 0.002 0.042 0.963 0.994 
 
WHR -0.362 0.191 0.059 0.148 
VATHU -0.012 0.048 0.803 0.913 
 
WHR-adjBMI -0.287 0.140 0.041 0.148 
VATSAT -0.017 0.044 0.707 0.913 
      
VATSAT-adjBMI -0.021 0.042 0.616 0.913 
      
WHR -0.008 0.013 0.546 0.913 
      
WHR-adjBMI -0.007 0.013 0.611 0.913 
      
P-values and q-values < 0.05 are in bold. 
*MR results taken from Egger's method as (unbalanced) horizontal pleiotropy was significant.                                                                                                                              
^significant heterogeneity (p = 0.0217).  
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Table 5   Top 3 genes shared between SCZ/BD and CM traits 
SCZ Bipolar disorder 
Trait Top 3 genes SNP Tdr11 Trait Top 3 genes SNP Tdr11 
Adiponectin GNL3 rs1108842 1.000  Adiponectin PBRM1 rs2083180 0.925 
  ZNF664 rs11057409 0.998    TWF2 rs353547 0.863 
  SEMA3G rs648514 0.993    ADIPOQ rs12495941 0.805 
BMI SLC39A8 rs13107325 1.000  BMI LMX1B rs7857133 0.975 
  NT5C2 rs11191582 1.000    CADM2 rs9829032 0.972 
  FOXO3 rs9400239 1.000    GIPC2 rs11162405 0.971 
CAD PFN1P11 rs11191416 1.000  CAD WBP1L rs284863 0.769 
  FES rs2521501 1.000    SERBP1P3 rs73082037 0.724 
  NT5C2 rs79780963 0.999    HDAC9 rs12670036 0.715 
DM MPHOSPH9 rs1727313 0.990  DM PCBD2 rs7728823 0.894 
  TLE1 rs2796441 0.988    SFMBT1 rs9865094 0.851 
  PROX1 rs340835 0.986    ABCB9 rs4275659 0.808 
FG PROX1-AS1 rs7529073 0.996  FG FEN1 rs4246215 0.828 
  IFT172 rs2272417 0.986    MRPL33 rs4666024 0.691 
  DPYSL5 rs10196501 0.975    BABAM2 rs937813 0.619 
FG  PROX1-AS1 rs7529073 0.999  FG  FEN1 rs4246215 0.754 
adjBMI SYNGAP1 rs411136 0.988  adjBMI MRPL33 rs9678336 0.569 
  DPYSL5 rs920435 0.983    BABAM2 rs937813 0.568 
Fat % TUFM rs4788099 0.995  Fat % NEXN rs1780050 0.983 
  CRTC1 rs757318 0.995    SORT1 rs1278664 0.978 
  DNAH10 rs7133378 0.995    LINC01830 rs2339519 0.918 
HDL SLC39A8 rs13107325 1.000  HDL PGAP3 rs2517956 1.000 
  C12orf65 rs1879379 1.000    TCAP rs113612868 0.994 
  NFATC3 rs8044995 1.000    VARS2 rs4678 0.970 
INS PSIP1 rs10283923 0.889  INS ANKS1B rs923724 0.780 
  ANKS1A rs2820237 0.883    ANKS1A rs847846 0.712 
  ANKS1B rs923724 0.836    CEP68 rs2723086 0.711 
INS GPN1 rs10173720 0.946  INS ANKS1A rs847846 0.816 
adjBMI ANKS1A rs2820237 0.941  adjBMI TMEM131 rs17424787 0.804 
  PPARG rs6802898 0.940    TET2 rs9884482 0.758 
DM-2ndset KCNQ1 rs234868 0.988  DM-2ndset OR12D3 rs3749971 0.820 
  CDKAL1 rs4712556 0.975    PPM1F rs1005579 0.812 
  PSMD6 rs3816157 0.945    ASAP2 rs7605582 0.811 
LDL STK19 rs389883 1.000  LDL SP4 rs12668354 0.956 
  SUGP1 rs2074550 0.999    ATXN7L2 rs2781553 0.945 
  SP4 rs7811417 0.995    MED24 rs12309 0.923 
Leptin PTPN7 rs9077 0.785  Leptin MLN rs3828783 0.551 
  LINC02029 rs900400 0.761    
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  MLN rs3828783 0.760          
Leptin ADAMTSL3 rs4374136 0.868  Leptin TRANK1 rs4441609 0.620 
adjBMI HSPA12A rs3010476 0.729  adjBMI TRPC4AP rs6120812 0.585 
  YWHAE rs12936636 0.718    PAX8 rs2241975 0.532 
TC MSH5 rs3117577 1.000  TC PGAP3 rs2517956 0.999 
  TNXB rs1150753 1.000    TCAP rs113612868 0.994 
  PSORS1C1 rs3130557 1.000    SP4 rs12668354 0.971 
TG MSH5-SAPCD1 rs3131379 1.000  TG MAP1LC3A rs6059908 0.980 
  ATF6B rs1269852 1.000    LINC00243 rs886424 0.978 
  PSORS1C1 rs3130557 1.000    GGT7 rs11546155 0.952 
WHR- CCDC92 rs4765219 0.998  WHR- C1orf105 rs4916261 0.870 
  BCL11B rs1257432 0.994    IKZF3 rs907092 0.863 
  WSCD2 rs3764002 0.989    HOTTIP rs17428025 0.855 
WHR- ITIH1 rs2710323 1.000  WHR- C1orf105 rs6700880 0.934 
adjBMI STAB1 rs1010554 1.000  adjBMI GNL3 rs1108842 0.920 
  RFLNA rs11057409 0.999    HLA-DMA rs9276931 0.878 
DBP SLC39A8 rs13107325 1.000  DBP CYP1A2 rs11072506 0.961 
  FURIN rs17514846 1.000    ZSCAN12 rs2232423 0.921 
  BORCS7-ASMT rs11191454 0.999    OR2B2 rs61742093 0.915 
SBP CNNM2 rs11191548 1.000  SBP CYP1A2 rs11072506 0.871 
  CYP17A1 rs17115100 1.000    EDEM2 rs3746429 0.723 
  FURIN rs17514846 1.000    NMT1 rs4793172 0.664 
PAT CEBPA-AS1 rs16967952 0.828  PAT (no SNP with Tdr11 > 0.5) 
  HS3ST4 rs4787333 0.730    
  PLAGL1 rs9399468 0.700          
PAT CEBPA-AS1 rs16967952 0.855  PAT NEK4 rs2072390 0.581 
adjHtWt OTX2-AS1 rs762098 0.727  adjHtWt LHB rs6509412 0.549 
  NEK4 rs2072390 0.712          
SAT PTPRK rs9375544 0.823  SAT GSDMA rs3859192 0.835 
  IZUMO1 rs8106205 0.776    PGAP3 rs903501 0.637 
  SPTSSB rs464766 0.747    INO80D rs817998 0.554 
SATHU WDR82 rs6445358 0.796  SATHU MYRIP rs2679799 0.524 
  SMG6 rs2019872 0.785    
  C16orf45 rs222129 0.571          
VAT ARMC4 rs11006760 0.786  VAT (no SNP with Tdr11 > 0.5) 
  CUL3 rs11681451 0.723    
  SERPINI1 rs2055026 0.710          
VAT EYS rs4710261 0.840  VAT (no SNP with Tdr11 > 0.5) 
adjBMI PEPD rs3786897 0.805  adjBMI 
  ALG12 rs9616370 0.762          
VATHU WDR82 rs6445358 0.878  VATHU PHF7 rs2272088 0.632 
25 
 
  PBRM1 rs10510760 0.664    ITIH3 rs2240919 0.541 
  SMG6 rs2019872 0.628          
VATSAT EYS rs4710261 0.883  VATSAT CADM2 rs6781999 0.523 
  ELP3 rs3757894 0.852    
  PEPD rs3786901 0.819          
VATSAT ELP3 rs3757894 0.823  VATSAT (no SNP with Tdr11 > 0.5) 
adjBMI EYS rs4710261 0.817  adjBMI 
  PEPD rs3786901 0.798          
The above tables displays genes with mapping to SNPs that remained after LD-clumping. Mapping was performed by the 
program BioMart. Please refer to Table 1 for abbreviation of the metabolic traits. Please refer to Supplementary Tables for 
detailed results for all shared SNPs with tdr11>0.5. 
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Table 6   Selected top pathways derived from SNPs shared between SCZ/BD and cardiometabolic traits 
Pathway Freq AvgRank Present_In 
SCZ    
Neuronal System 11 40.5 BMI , CAD , DM , HDL , DM-2nd_set , TC , TG , VAT , VAT-adjBMI , 
VATSAT-adjBMI , WHR  
Insulin secretion - Homo sapiens (human) 9 21 DBP , DM , FG , FG-adjBMI , Fat-percentage , HDL , DM-2nd_set , SBP , TG  
VEGF 9 37.4 BMI , CAD , LDL , PAT , TC , TG , VAT-adjBMI , WHR , WHR-adjBMI  
Aldosterone synthesis and secretion - Homo sapiens (human) 9 42 BMI , CAD , FG , HDL , TC , TG , VAT , WHR , WHR-adjBMI  
RXR and RAR heterodimerization with other nuclear receptor 9 65.6 BMI , CAD , DM , FG-adjBMI , HDL , LDL , TC , TG , WHR-adjBMI  
Axon guidance 8 34.8 BMI , CAD , FG , Fat-percentage , Leptin , TG , VATSAT , VATSAT-adjBMI  
Statin Pathway 7 22.3 BMI , CAD , Fat-percentage , HDL , LDL , TC , TG  
Signaling by EGFR 7 51.7 BMI , FG , Fat-percentage , HDL , Leptin , WHR , WHR-adjBMI  
Lipoprotein metabolism 6 3.2 CAD , Fat-percentage , HDL , LDL , TC , TG  
Proton Pump Inhibitor Pathway, Pharmacodynamics 6 29.8 BMI , DBP , DM , FG , SAT , TG  
EPO signaling 6 39.2 LDL , PAT , TC , TG , VAT-adjBMI , WHR-adjBMI  
IL-7 signaling 6 42.2 LDL , PAT , TC , TG , VAT-adjBMI , WHR-adjBMI  
Brain-Derived Neurotrophic Factor (BDNF) signaling pathway 6 42.3 BMI , CAD , Fat-percentage , HDL , Leptin , WHR  
cAMP signaling pathway - Homo sapiens (human) 6 48.5 BMI , CAD , FG , HDL , Leptin , WHR  
    
Bipolar disorder    
Chromatin modifying enzymes 7 53.1 BMI , HDL , DM-2ndset , LDL , PAT-adjHtWt , TC , TG  
Alpha Linolenic Acid and Linoleic Acid Metabolism 5 53.2 FG , FG-adjBMI , HDL , LDL , TC  
Antigen processing and presentation - Homo sapiens (human) 4 12.2 TC , TG , WHR , WHR-adjBMI  
Cell adhesion molecules (CAMs) - Homo sapiens (human) 4 17 TC , TG , WHR , WHR-adjBMI  
Amyloid fiber formation 4 20.5 HDL , DM-2ndset , TC , TG  
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HATs acetylate histones 4 22.8 HDL , DM-2ndset , TC , TG  
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA 
expression 
4 23.5 HDL , DM-2ndset , TC , TG  
TGF-beta super family signaling pathway canonical 4 27.5 CAD , LDL , SAT , TC  
Phagosome - Homo sapiens (human) 4 28.5 TC , TG , WHR , WHR-adjBMI  
Positive epigenetic regulation of rRNA expression 4 29.5 HDL , DM-2ndset , TC , TG  
 
Freq: frequency of being top-listed across all CM traits; AvgRank, average rank of pathway if top-listed.   
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